M&A / Deals Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal BioPharma DiveThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.Rare DiseaseRead full story pharminent July 1, 2026 (Last updated: July 1, 2026) BioPharma Dive The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot programNext: Ipsen Acquires Memo Therapeutics for Up to €700M in Second Deal in Three Days Related Stories M&A / Deals Zymeworks cuts deal to buy Theravance for $929m in cash pharminent June 29, 2026 M&A / Deals Ipsen charts $1.75bn course for Kartos acquisition pharminent June 29, 2026 M&A / Deals Immunai and Boehringer partner to identify T-cell targets pharminent June 26, 2026
